Literature DB >> 18528966

N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification.

Cecilia P Chung1, Joseph F Solus, Annette Oeser, Ingrid Avalos, Daniel Kurnik, Paolo Raggi, C Michael Stein.   

Abstract

OBJECTIVE: Cardiovascular mortality is increased in systemic lupus erythematosus (SLE). Increased plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with cardiovascular morbidity and mortality in the general population. We examined the hypothesis that NT-proBNP concentrations are higher in patients with SLE, and are related to inflammation, augmentation index, coronary atherosclerosis, and cardiovascular risk factors.
METHODS: Serum concentrations of NT-proBNP were measured in 113 patients with SLE and in 80 control subjects. Coronary calcification and augmentation index were measured by electron beam computed tomography and noninvasive pulse wave analysis, respectively.
RESULTS: Patients with SLE had higher concentrations of NT-proBNP [median 38.6 (interquartile range 2.5-126.9) pg/ml] than controls [11.7 (1.6-47.9) pg/ml] (p = 0.002). Augmentation index was higher in patients with SLE [25.0% (20.5%-31.5%)] than controls [20.5% (12.0%-29.0%)] (p = 0.04). In patients with SLE, NT-proBNP concentrations were associated with disease damage (rho = 0.31, p < 0.001) and duration (rho = 0.21, p = 0.02) but not with disease activity, C-reactive protein, erythrocyte sedimentation rate, tumor necrosis factor-alpha, interleukin 6, coronary calcium score, or augmentation index (all p > or = 0.18).
CONCLUSION: Patients with SLE have increased concentrations of NT-proBNP, but this is not explained by atherosclerotic burden, augmentation index, or inflammatory state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528966      PMCID: PMC2754266     

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  36 in total

1.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

Authors:  R W Troughton; C M Frampton; T G Yandle; E A Espiner; M G Nicholls; A M Richards
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Eric P Leip; Emelia J Benjamin; Peter W F Wilson; Patrice Sutherland; Torbjorn Omland; Ramachandran S Vasan
Journal:  Am J Cardiol       Date:  2002-08-01       Impact factor: 2.778

3.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

4.  Increased cardiac BNP expression associated with myocardial ischemia.

Authors:  J P Goetze; C Christoffersen; M Perko; H Arendrup; J F Rehfeld; J Kastrup; L B Nielsen
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

5.  Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.

Authors:  Alain Rudiger; Stefan Gasser; Manuel Fischler; Thorsten Hornemann; Arnold von Eckardstein; Marco Maggiorini
Journal:  Crit Care Med       Date:  2006-08       Impact factor: 7.598

6.  Natriuretic peptide system gene expression in human coronary arteries.

Authors:  Victor H Casco; John P Veinot; Mercedes L Kuroski de Bold; Roy G Masters; Michelle M Stevenson; Adolfo J de Bold
Journal:  J Histochem Cytochem       Date:  2002-06       Impact factor: 2.479

7.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

8.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Authors:  Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

9.  The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.

Authors:  I Raymond; B A Groenning; P R Hildebrandt; J C Nilsson; M Baumann; J Trawinski; F Pedersen
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

10.  Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification.

Authors:  Elizabeth Turner; Victor Dishy; Cecilia P Chung; Paul Harris; Rosanna Pierces; Yu Asanuma; Annette Oeser; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; C Michael Stein
Journal:  Vasc Health Risk Manag       Date:  2005
View more
  6 in total

1.  Association of N-terminal pro-brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus.

Authors:  Diana Goldenberg; Emily Miller; Michelle Perna; Naveed Sattar; Paul Welsh; Mary J Roman; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-01

Review 2.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

3.  Inflammation and Circulating Natriuretic Peptide Levels.

Authors:  Hannah Fish-Trotter; Jane F Ferguson; Nirav Patel; Pankaj Arora; Norrina B Allen; Katherine N Bachmann; Lori B Daniels; Muredach P Reilly; Joao A C Lima; Thomas J Wang; Deepak K Gupta
Journal:  Circ Heart Fail       Date:  2020-06-08       Impact factor: 8.790

4.  The prevalence of metabolic syndrome is increased in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Dilek Barutcu Atas; Halil Atas; Tuba Nur İzgi; Arzu Velioglu; Hakki Arikan; Fatma Alibaz Oner; Haner Direskeneli; Serhan Tuglular; Ebru Asicioglu
Journal:  Int Urol Nephrol       Date:  2021-01-02       Impact factor: 2.370

5.  Prediction of subclinical left ventricular dysfunction by speckle-tracking echocardiography in patients with anti-neutrophil cytoplasmic antibody--associated vasculitis.

Authors:  Tuba Nur İzgi; Dilek Barutcu Ataş; Halil Ataş; Dursun Akaslan; Can Ilgın; Arzu Velioğlu; Hakkı Arıkan; Fatma Alıbaz-Öner; Haner Direskeneli; Serhan Tuğlular; Ebru Aşıcıoğlu
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

6.  Utility of Coronary Calcium Scoring (CCS) in Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis - A Systematic Review.

Authors:  Sohail Farshad; Alexandra Halalau; Whitney Townsend; Elena Schiopu
Journal:  ACR Open Rheumatol       Date:  2020-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.